INNOCARE (09969): ICP-488 is significantly effective in treating moderate to severe plaque psoriasis, and has shown good safety and tolerability.

INNOCARE (09969) announced that the phase II study data for CP-488 in the treatment of moderate to severe plaque psoriasis has been presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, the most influential international conference in the field of dermatology, the relevant data was presented in the form of a major oral presentation. The study results showed that ICP-488 at doses of 6 mg once daily (QD) and 9 mg once daily demonstrated significant efficacy in patients with psoriasis, and also showed good safety and tolerability, providing a valuable treatment option for patients with moderate to severe psoriasis.